ALFA Finder| Revenue growth | 19.5% YoY |
|---|---|
| Margins | EBITDA margin expanded 530 bps YoY to 21.6% |
| Demand visibility | Strong, especially in Formulations (33% Q1 YoY growth) |
| Management confidence | High; citing integration success and well-defined growth strategy |
Growth
Q1 FY27 Revenue at ₹9,464 Mn (+19.5% YoY); EBITDA at ₹2,047 Mn (+59.2% YoY); PAT at ₹793 Mn (+114.9% YoY).
Outlook
Acquisition of Bio For Life (Italy) to drive companion animal segment; strong R&D pipeline with 85+ APIs and 105+ FDFs.
Risks
Higher ESOP costs due to amalgamation and hyperinflation adjustments in Turkey (Ind AS 29).
Last quarter's promises, checked
Delivered
- Guided 15% annual growth → delivered 19.5% YoY (= BEAT)
- Guided EBITDA run rate of INR 800 Cr → delivered INR 2,047 Mn for Q1 (= BEAT)
- Guided tax rate ~27% → delivered 27.8% (= BEAT)
Partly delivered
- Guided double-digit API growth → delivered 4% YoY in Q1 (= MISS)
Investor Presentation filed with NSE, NSE: VIYASH. Summary written with AI assistance from the document.
Viyash Scientific Ltd: key numbers
- Share price
- ₹255.33
- Market cap
- ₹11,285 Cr
- Revenue (annual)
- ₹3,420 Cr
- Net profit (annual)
- ₹177.3 Cr
- P/E (TTM)
- 65.9×Sector 43.8×
- Promoter holding
- 49.24%-12.07% QoQ
- FII holding
- 2.60%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Viyash Scientific Ltd
All →Viyash Scientific Employee Stock Options
Viyash Scientific allotted 228,408 shares under two employee stock option schemes. Paid-up capital rose to 44,19,91,958 shares of Rs.2 each.
Viyash Scientific Board Meeting Date
Viyash Scientific will hold a board meeting on 13 November 2026 to consider unaudited quarterly and half-yearly results. The trading window remains closed until 15 November 2026.
Viyash Scientific Merger & Restructuring Worth ₹3.8 Cr
Viyash's step-down subsidiary Alivira Vietnam was incorporated on 30 October 2026, with investment up to USD 400,000. It will distribute animal health products and APIs in Vietnam.
- Value
- ₹3.80 Cr
Viyash Scientific Management Change
Viyash Scientific Limited has appointed Dr. Mallikharjuna Rao Nagineni as Senior Vice President, Human Resources, succeeding the retiring Mr. Prasad Lad.
Viyash Scientific Capital Structure Change
White Oak Capital Management Consultants LLP disclosed the sale of 8,747,392 equity shares of Viyash Scientific Ltd, reducing its stake in the open market.
Viyash Scientific Other Announcement
Viyash Scientific Ltd filed its quarterly shareholding pattern for the period ending September 30, 2026, in compliance with SEBI Regulation 31.